Biopharmaceutical News and Research

RSS

Eli Lilly, Covance announce key milestones of their first-year partnership

Senior executives from Eli Lilly and Company and Covance Inc. announced Friday that the first year of their landmark alliance has been a win-win for both companies, enabling Lilly to expedite the flow of innovation within its pipeline in order to provide improved outcomes for individual patients.

27 Feb 2010

Shire receives marketing approval from FDA for VPRIV

Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.

27 Feb 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

Medical innovation and research: A real boon for American patients to live longer, healthier

An article in the Suislaw News recently highlighted the fact that medical innovation and research are enabling many people to live longer, healthier and more productive lives.

26 Feb 2010

UCB adopts Enterprise version of NextBio platform

NextBio, developer of an innovative software platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today announced a license agreement with global biopharmaceutical company UCB, for NextBio Enterprise. NextBio Enterprise offers life sciences organizations unique tools for knowledge discovery and collaboration, seamless integration of internal and external research data, and secure data access.

26 Feb 2010

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.

25 Feb 2010

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere’s Convertible Promissory Note to May 26, 2010.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has expanded its capabilities through the opening of a new early phase unit in Port Elizabeth, South Africa.

From Parexel 24 Feb 2010

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.

24 Feb 2010

Medical innovation: A real boon for American patients

An article in the Journal Miner recently highlighted the fact that many people are living longer, healthier and more productive lives thanks to medical innovation and research.

24 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund’s capital is from returning investors, and the fund’s partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.

22 Feb 2010

Shire reports total revenues of $3,008 million for 2009

Shire plc the global specialty biopharmaceutical company, announces results for the year to December 31, 2009.

22 Feb 2010

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

An article that recently appeared in El Tejano Magazine highlighted the fact that many Americans are living longer, healthier and more productive lives because of medical innovation and research.

20 Feb 2010

Pharmaceutical and biotechnology companies working on nearly 200 new medicines to treat diabetes

A Stratton Spotlight article recently highlighted a Centers for Disease Control and Prevention (CDC) survey that showed a dramatic rise in the number of diabetes cases during the last 10 years and noted that pharmaceutical research and biotechnology companies are working on nearly 200 new medicines to treat this debilitating disease.

19 Feb 2010

NeoStem closes share public offering; expects $6.9 million in net proceeds

NeoStem, Inc. ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today the closing of its previously announced 5,000,000 share public offering and the exercise of the over-allotment option in full by the underwriters for an additional 750,000 shares of the Company's common stock, bringing the total shares offered to 5,750,000.

19 Feb 2010

Biopharmaceutical News and Research

Eli Lilly, Covance announce key milestones of their first-year partnership

Shire receives marketing approval from FDA for VPRIV

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Medical innovation and research: A real boon for American patients to live longer, healthier

UCB adopts Enterprise version of NextBio platform

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Shire receives FDA Fast Track designation for REPLAGAL

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Medical innovation: A real boon for American patients

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

Shire reports total revenues of $3,008 million for 2009

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

Pharmaceutical and biotechnology companies working on nearly 200 new medicines to treat diabetes

NeoStem closes share public offering; expects $6.9 million in net proceeds

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News